. 2021 Mar 23;218(4):e20201605. doi: 10.1084/jem.20201605

Table 1. Clinical relevance of T_RM in patients with cancer.

Cancer types	T_RM phenotype	Correlation with clinical features	References
Breast cancer	CD8⁺, CD103⁺	Intratumoral CD103⁺CD8⁺ T cells are positively associated with RFS and OS in estrogen receptor–negative basal-like breast cancer.	Wang et al., 2016
		CD8⁺ T_RM gene signature is associated with improved DFS and OS in patients with TNBC.	Savas et al., 2018
		Levels of CD103⁺CD8⁺ T cells are higher in TNBCs in patients without tumor relapse than with tumor relapse.	Egelston et al., 2019
Bladder cancer	CD8⁺, CD103⁺, CD69⁺, CD49a⁺, PD-1⁺	Levels of CD103⁺CD8⁺ T cells are negatively associated with tumor size and are positively associated with OS and RFS.	Wang et al., 2015
		High T_RM tumor infiltration is associated with lower tumor stage.	Hartana et al., 2018
Cervical cancer	CD8⁺, CD103⁺, PD-1⁺, GzmB⁺	CD103 expression is associated with improved DSS.	Komdeur et al., 2017
		Prognostic benefit of increased CD103 expression is observed in patients treated with radiotherapy.
		Abundance of intraepithelial CD103⁺ cells is associated with improved DSS and DFS in patients with or without radio(chemo)therapy.
Colorectal cancer	CD8⁺, CD103⁺	High density of CD103⁺ cells is associated with DFS.	Huang et al., 2017
		High density of CD103⁺ cells is negatively associated with OS and DFS in patients with KRAS WT tumors.
Endometrial cancer	CD8⁺, CD103⁺, PD-1⁺	CD103⁺ cells are associated with prolonged DSS.	Workel et al., 2016
Esophageal cancer	CD8⁺, CD103⁺, PD-1⁺, TIM3⁺	High density of CD103^hiCD8^hi cells is associated with improved OS.	Han et al., 2020
Gastric cancer	CD103⁺, CD69⁺, PD-1⁺, TIGIT⁺, CD39⁺	Presence of CD8⁺CD103⁺ cells is associated with improved OS.	Lin et al., 2020
Hepatocellular carcinoma	CD8⁺, CD103⁺	High density of CD8⁺CD103⁺ cells is associated with improved OS.	Lim et al., 2019
Head and neck cancer	CD8⁺, CD103⁺, CD39⁺	High frequencies of CD103⁺CD39⁺ cells are associated with improved OS.	Duhen et al., 2018
		High expression of CD103 is associated with improved OS.
Lung cancer	CD8⁺, CD103⁺ CD69⁺, CD49a⁺, PD-1⁺, 4-1BB⁺, CXCR6⁺ CD39⁺, TIM3⁺	High levels of CD103⁺ cells are associated with improved OS in total tumor and stromal region.	Djenidi et al., 2015
		High levels of CD103⁺ cells are associated with improved DFS in total tumor, epithelial tumor islets, and stromal region.	Ganesan et al., 2017
		High density of CD103⁺ cells is associated with improved OS.	Duhen et al., 2018
		High expression of both CD103 and CD39, as well as CD103 alone, is associated with improved OS.	Koh et al., 2017
		High numbers of intratumoral, but not stromal, CD103⁺ cells are associated with prolonged DFS and OS.	Clarke et al., 2019
		PD-1⁺TIM3⁺ cells are enriched in responders to anti–PD-1 therapy.	Nizard et al., 2017
		High intratumoral CD103⁺ cells are associated with improved OS.
Melanoma	CD8⁺, CD103⁺, CD69⁺, CD49a⁺, PD-1⁺, LAG-3⁺, GzmB⁺	High levels of CD49a expression are associated with improved DFS and OS.	Murray et al., 2016; Edwards et al., 2018; Menares et al., 2019
		Increased numbers of CD69⁺CD103⁺CD8⁺ cells are associated with improved OS in immunotherapy-naive patients.
		Enrichment of T_RM gene signature is associated with improved OS.
Ovarian cancer	CD8⁺, CD103⁺, PD-1⁺, CD3⁺	Presence of CD103⁺ cells is associated with increased DSS in HGSOC and mucinous cancers.	Webb et al., 2014
		Patients with HGSOC, containing both CD103⁺ and PD-1⁺ cells, are associated with increased DSS.	Webb et al., 2015
		CD103⁺ cell numbers are associated with improved DSS in patients treated with PS.	Bösmüller et al., 2016
		High infiltration of CD103⁺ cells in tumor parenchyma of primary tumors is associated with improved 10-yr OS.	Komdeur et al., 2016
			Santoiemma et al., 2016
Pancreatic cancer	CD8⁺, CD103⁺	Increased ratio of CD8⁺CD103⁺ cells to CD8⁺CD103⁻ cells is associated with improved DFS.	Lohneis et al., 2017

DFS, disease-free survival; DSS, disease-specific survival; HGSOC, high-grade serous ovarian cancer; OS, overall survival; PS, primary surgery and adjuvant chemotherapy; RFS, relapse-free survival; TIGIT, T cell immunoreceptor with immunoglobulin and ITIM domains; TNBC, triple-negative breast cancer.

Table 1. Clinical relevance of TRM in patients with cancer.

Table 1. Clinical relevance of T_RM in patients with cancer.